TAILOR: For patients who have not received treatment for their CLL

Therapy on Trial: Ibrutinib & Venetoclax OR Ibrutinib Alone

Study Information

Study Title

Multi-arm Study to Support the Ability to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR Study)

Study Summary

The purpose of this clinical trial is to evaluate the efficacy of I+V and ibrutinib monotherapy regimens using a tailored treatment approach in which dosing of ibrutinib is either proactively reduced or reactively modified (per the label) in response to AEs, compared with clinical trial-based historical controls of ibrutinib monotherapy and I+V.

Disease State

Chronic Lymphocytic Leukemia

Principal Investigator

Megha Shah, MD

Phase III

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

Contact HHO

All questions and feedback are welcome, anytime.

    About HHO

    Hunterdon Hematology Oncology is a community oncology group, dedicated to fighting cancer in this community and across the region. Our Doctors, Physician’s Assistants and Nurses work tirelessly. They fight hard so that you can win.


    Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.

      © HHO 2022. All rights reserved. Designed by DRAW